ISSN: 2231-3656

International Journal of Pharmacy and Industrial Research (IJPIR)

IJPIR |Vol. 16 | Issue 3 | July–Sep 2026

www.ijpir.com

DOI: https://doi.org/10.61096/ijpir.v16.iss3.2026.713-723

Navigating The FDA Regulatory Pathway for Apple's Sleep Apnea Notification Feature: A Regulatory Case Study of Software as a Medical Device (SAMD)

[1]K. Lakshmi Sravani*, [2]B Lakshmi Satya, Dr C Soujanya[3*]

[1]Assistant Professor, Department of Regulatory Affairs, Vishnu Institute of Pharmaceutical Education & Research,

[2]Associate Professor,Department of Pharmaceutics,Vishnu Institute of Pharmaceutical Education & Research

[3]Associate Professor & HoD,Department of Regulatory Affairs,Vishnu Institute of Pharmaceutical Education & Research*

Corresponding Author: ***Dr C Soujanya***

Email Id: soujanya.c@viper.ac.in

Published on: 20.07.2026
Published by: Futuristic Publications

Abstract: Software-based medical innovations are changing healthcare by enabling non-invasive illness screening with wearable devices. As their clinical use expands, there is a need for robust regulatory pathways to assure safety, efficacy and software reliability without limiting innovation. This paper presents a regulatory case study of Apple's Sleep Apnea Notification Feature, which was successfully approved under the United States Food and Drug Administration Premarket Notification (510(k)) pathway. The study evaluates the manufacturer's regulatory approach including algorithm development, software validation, and generation of pre-clinical and clinical data, risk management and regulatory decision making. What this case indicates is that in order for you to be able to secure a successful marketing authorization you need good scientific proof, a well-developed software quality management system and compliance with the existing regulatory criteria. These findings offer important regulatory lessons for the development and evaluation of future software-based medical innovations and underscore the need for evidence-based regulatory methods to advance digital health innovation.

Keywords: Software as a Medical Device, Sleep Apnea, Premarket Notification, Food and Drug Administration, Digital Health, Wearable Medical Devices

1. Introduction

Obstructive sleep apnea (OSA) is the most common chronic sleep associated breathing illness defined by repetitive episodes of partial or total obstruction of the upper airway during sleep leading to intermittent hypoxia, sleep fragmentation and decreased sleep quality. It has been linked to a number of poor health consequences including hypertension, cardiovascular illnesses, stroke, metabolic disorders and reduced cognitive function. Despite its high incidence, a considerable proportion of affected persons remain undiagnosed due to restricted access to sleep laboratories, high expense of diagnostic procedures and discomfort of nightly polysomnography (PSG) which remains the gold standard for diagnosis. These constraints have motivated the development of novel digital health solutions that can enable early detection of persons at risk for sleep apnea.

Recent developments in wearable sensors, artificial intelligence (AI) and machine learning (ML) have greatly enhanced the role of digital health technology in disease screening and monitoring of patients.

Smart wearable devices can continually gather physiological characteristics, such as heart rate, breathing, movement and sleep related data. This enables the creation of software algorithms that can detect clinically relevant health issues. Such technological advancement has expedited the rise of Software as a Medical Device (SaMD). SaMD is defined by the International Medical Device Regulators Forum (IMDRF) as software designed for medical purposes that accomplishes such goals without being part of a physical medical device. These technologies provide tremendous prospects to improve health care delivery but also pose specific regulatory problems relating to software quality, clinical validation, cybersecurity, risk management and lifecycle maintenance. Recognizing these problems, the U.S. Food and Drug Administration (FDA) has developed a risk-based regulatory framework for evaluating Software as a Medical Device. Depending on the intended application, technological characteristics and the clinical risk associated with the SaMD product, the Premarket Notification [510(k)], De Novo classification and Premarket Approval (PMA) pathways may be used to examine SaMD products. In addition to the functionality of the program, the regulatory review covers software development methods, verification and validation operations, clinical performance, risk management, labeling, and post-market concerns. Collectively, this regulatory strategy seeks to provide reasonable assurance that software-enabled medical products are safe and effective, while allowing for ongoing innovation in digital health care.

One good example of the successful regulatory translation of wearable digital health technologies into clinical practice is the Sleep Apnea Notification Feature of the Apple Watch. The feature uses verified software algorithms to assess patterns of breathing disturbance while sleeping, and inform users who may be at risk of mild to severe sleep apnea. This feature received market permission from the FDA in September 2024, under the Premarket Notification (510(k)) procedure, after an assessment of evidence in relation to software performance, clinical validation, risk management and overall safety. This regulatory milestone points to the increasing importance of evidence-based evaluation for AI-enabled wearable medical technologies and shows how innovative software solutions can meet established regulatory requirements.

Wearable technologies and AI applications in sleep medicine have been mentioned in previous papers, however, relatively little attention has been given to the regulatory pathway in which these software-based solutions obtain market authorization. The present essay thus offers a regulatory case study of Apple's Sleep Apnea Notification Feature, with a particular focus on its FDA Premarket Notification (510(k)) method. The paper describes the regulatory approach, evidence collection, software validation, clinical evaluation, and regulatory considerations that supported FDA clearance, as well as critical regulatory insights pertinent to the future development and review of Software as a Medical Device.

2. Regulatory Framework for SaMD

2.1 FDA Risk-Based Classification of SaMD

The FDA regulates SaMD based on the level of risk of its intended usage. Devices intended for diagnosis or clinical decision support are classified to an appropriate risk class according to their intended function, the relevance of the information supplied and the potential effect on patient safety. Apple's Sleep Apnea Notification Feature earned FDA clearance under the Premarket Notification (510(k)) procedure as a Class II medical device, demonstrating substantial equivalence to a legally marketed predicate product. This risk-based regulatory approach allows the FDA to strike a reasonable balance between innovation and patient safety by requiring that moderate risk devices undergo appropriate scientific and regulatory review before they may be marketed.

2.2 Software Life Cycle and Quality Management

The FDA expects that manufacturers of Software as a Medical Device will have in place extensive software development and quality management practices across the product life cycle. Software documentation should reflect systematic design, verification, validation, risk management, change control and post-market maintenance. Regulatory review generally recognizes international standards such as IEC 62304 for software life-cycle processes and ISO 14971 for medical device risk management. Software that adheres to these criteria is able to operate reliably for its expected life cycle and reduces the risks associated with software failures.

Besides the software life-cycle management and quality systems, the FDA mandates Software as a Medical Device producer to generate adequate scientific and regulatory data to demonstrate the safety, effectiveness and clinical performance of the device prior to market authorization. The amount and quantity of this evidence will depend on the device categorization, intended use and appropriate regulatory procedure. The assessment of software-enabled medical devices submitted to FDA for approval is based on these regulatory criteria.

3. Case Study: Apple's Sleep Apnea Detection Algorithm

3.1 Algorithm Development:

Apple's Sleep Apnea Notification Feature (SANF) is a deep learning model that utilizes the accelerometer data from the Apple Watch to detect breathing problems. The training set consisted of > 11,000 nights of concurrent accelerometer data from the Apple Watch and reference recordings from polysomnography (PSG) and Home Sleep Apnea Test (HSAT). The dataset comprises participants with varied levels of sleep apnea severity (normal [AHI 0 to <5], mild [AHI 5 to <15], moderate [AHI 15 to <30], and severe [AHI ≥30]) to adequately represent the disorder.

The data was divided into four separate sets: Training, Validation, Test and Sequestration. The model was trained with the Training set and the Validation set was utilized for early stopping and threshold optimization. The model was evaluated often on the Test set during development. At the end of development, the model was evaluated on the Sequestration set to ensure it was not overfitted on the training data.

This methodological strategy ensured no overlap in individuals between the several datasets and that the distributions of crucial parameters such as age, sex, BMI, race, ethnicity and sleep apnea severity were balanced across all groups. The development approach was intended such that the final model was resilient, generalizable and adaptable to a diverse real-world population. This extensive training and validation methodology highlights the robustness and effectiveness of the algorithm for sleep apnea identification for different demographic groups.

3.2 Regulatory Strategy

An important factor for the successful market authorization of a SaMD is the selected regulatory strategy. The USFDA adopts a risk-based regulatory framework to examine software-enabled medical devices to ensure that they show sufficient safety, effectiveness, and clinical performance prior to commercialization. Manufacturers may seek authorization via the Premarket Notification [510(k)], De Novo classification, or Premarket Approval (PMA) pathway, depending on the planned use of the device, technological attributes and related level of risk. The correct regulatory pathway is important because it will dictate the type and amount of scientific evidence, technical data and clinical validation that will be required for regulatory review.

SANF was classified as a Class II SaMD and was cleared by the FDA through the Premarket Notification (510(k)) pathway (K240929). This path was chosen based on a demonstration of substantial equivalence to a legally marketed predicate device with the same intended application and technological attributes. Conversely, the Premarket Approval pathway requires substantial independent evidence to demonstrate safety and effectiveness, while the 510(k) pathway allows market clearance if a manufacturer can show that the new device performs similarly to an already legally marketed device, without raising new safety or effectiveness concerns.

For the regulatory submission, Apple had to provide extensive documentation regarding the software architecture, use case, device functionality, algorithm design, software development process, risk management activities, verification and validation procedures, clinical performance data, cybersecurity precautions, labeling, and post-market considerations. Collectively, these statistics allow the FDA to review whether the software functions as intended under the conditions of its intended usage, and if possible hazards have been effectively recognized, evaluated, and controlled throughout the product life cycle.

Generating strong analytical and clinical evidence that supports the performance of the sleep apnea detection algorithm was a core element of the regulatory strategy. The FDA wants manufacturers to demonstrate that the outputs of the software are scientifically valid, therapeutically relevant, and reproducible in the targeted patient population. Accordingly, Apple developed a robust development and evaluation process that comprised algorithm training, independent performance testing, verification and validation operations, and clinical evaluation against known reference standards. The software's generalizability and dependability were additionally supported by the participation of broad demographic groups and therapeutically relevant datasets.

Risk management was another key element of Apple's regulatory strategy. Potential risks associated with inaccurate notifications, software malfunction, data integrity, and cybersecurity vulnerabilities were systematically identified and addressed through algorithm optimization, software validation, secure data management practices, and ongoing performance monitoring, consistent with internationally accepted medical device risk management principles. These actions supported a good

benefit-risk balance and the regulatory judgment that the device could be safely used as a screening tool for suspected sleep apnea.

Apple's whole regulatory process exemplifies well the multidisciplinary aspect of SaMD evaluation, where software engineering, clinical evidence, quality management, risk assessment, cybersecurity, and regulatory compliance all contribute to successful market licensing. The case also illustrates that FDA approval of AI-enabled wearable technologies depends not only on technical innovation but also on generating extensive regulatory evidence that the software reliably performs the intended medical purpose, while simultaneously ensuring patient safety and data security.

The overall regulatory workflow followed for obtaining FDA clearance of Apple's Sleep Apnea Notification Feature through the Premarket Notification (510(k)) pathway is illustrated in Figure I.



Fig 1: FDA Regulatory Pathway for Apple's Sleep Apnea Notification Feature (510(k)
Source: Developed by the author based on publicly available FDA guidance documents and the FDA 510(k) review process.

3.3 Regulatory Evidence Generation and Validation

The generation of robust scientific evidence is a fundamental prerequisite in the regulatory licensing of SaMD. Producers can be required to demonstrate under FDA requirements that the software performs consistently, correctly and safely across its intended life cycle. Regulatory evidence should demonstrate analytical validity, clinical validity and overall device performance through methodical software development, preclinical testing, verification and validation, clinical evaluation and robust risk management. The kind and level of proof required are determined by the planned usage of the device, its technological characteristics, its risk rating and the likely influence of incorrect software outputs on patient safety.

The regulatory examination of AI-powered wearable medical devices must move beyond checking that the algorithm is right. It must also ensure that the software performance is reliable, repeatable, resilient and generalizable in real-world contexts. Hence, producers must demonstrate objective evidence that software outputs are therapeutically relevant to various patients' demographics and that the benefit-risk characteristics are acceptable. The thorough documentation of software development, testing activities, validation methodologies and clinical evidence helps regulatory agencies to assess whether the program

consistently performs its intended medical function without posing an unacceptable risk of harm to the user.

Apple's evidence generation strategy for the SANF was built to meet these regulatory standards, including algorithm development, software verification and validation, preclinical performance testing, and clinical evaluation. The algorithm's analytical and clinical performance was demonstrated with many independent datasets, defined clinical reference standards and statistically confirmed performance indicators. This comprehensive evaluation provided the scientific data needed to support substantial equivalence under the FDA's Premarket Notification (510(k)) process, and offered reasonable assurance of the safety, effectiveness and reliability of the device.

3.3.1 Preclinical Design and Algorithm Testing:

Apple has developed and tested a Breathing Disturbances measure and associated sleep apnea warning algorithm for the Apple Watch, to alert users they may be suffering from sleep apnea. Algorithm development was performed using 3,936 nights of in-lab and at-home sleep recordings from 2,160 people and performance testing was performed on a separate set of 7,220 nights from 2,542 adults. The design had a population of varying ages, gender, race, ethnicity and BMI. Data from both typical and severe cases of apnea were included. Apple used strict polysomnography (PSG) criteria with hypopneas defined by 4% oxygen desaturation. The system examines breathing data, every 30 days, and needs a minimum of 10 nights to give a reliable analysis. It is optimized for high specificity (95.9%) to prevent false positives, and has a sensitivity of 66.6%. Further assessments indicated that demographics and physiology did not significantly effect performance, further confirming the resilience of the algorithm across populations. We deliberately chose an operating point on the receiver operating characteristic (ROC) curve to balance sensitivity and specificity, with the aim of providing meaningful notifications, without inundating consumers with false positives.

3.3.2 Clinical Evaluation:

An examination of secondary endpoints was performed to evaluate the accuracy of individual night Breathing Disturbances readings where the ground truth was specified by the HSAT reference device. A novel assessment method was used to compare the aligned Apple Watch data with the HSAT measurements. The approach includes a funnel-shaped zone which provides for a greater tolerance to error as the genuine AHI value increases. The technique is based on the premise that the bigger errors are more tolerable at higher AHI levels, e.g. in severe sleep apnea, than at lower AHI values where minor errors are more important. For example, a mistake of 3 points is less relevant if the genuine AHI is 50 (severe) than if it is 5 (moderate). This performance zone is independent of percentage-error measurements, which would be exceedingly restrictive at low AHI values.

The clinical study was designed to establish, from a regulatory perspective, that the Sleep Apnea Notification Feature provided clinically reliable and reproducible outputs relative to accepted diagnostic reference criteria. The use of HSAT as the reference device provides clinically relevant evidence to support the analytical and clinical validity of the algorithm under the intended conditions of use. The predefined performance evaluation technique also provided evidence that clinically significant disparities across different severities of sleep apnea were well assessed and reflected real-world clinical practice. The inclusion of objective performance indicators and endpoints that have been statistically validated added to the overall strength of the evidence of the program's safety, effectiveness and clinical utility. These results were important to support the FDA's determination that the device met the regulatory requirements for clearance to market through the Premarket Notification (510(k)) process.

Table I: Major FDA Review Activities During the 510(k) Evaluation

Stage	Responsible Office	Major Activities
Device Development	Manufacturer	Algorithm development, software design, intended use definition
Verification & Validation	Manufacturer	Software testing, verification, validation, bug fixing
Clinical Evaluation	Manufacturer	Clinical studies, statistical analysis, performance evaluation
510(k) Preparation	Manufacturer	Device description, risk analysis, labeling, software documentation

Submission	FDA Document Control Center (DCC)	Receipt and administrative processing of the application
Acceptance Review	CDRH	Refuse-to-Accept (RTA) screening for completeness
Scientific Review	CDRH Review Team	Evaluation of substantial equivalence, software, clinical evidence, risk management, cybersecurity, and labeling
Interactive Review	FDA and Manufacturer	Clarification requests and additional information, if required
Final Decision	FDA	Determination of Substantial Equivalence (SE) or Not Substantially Equivalent (NSE)
Post-market Activities	Manufacturer and FDA	Complaint handling, software maintenance, updates, adverse event reporting

3.4 FDA Regulatory Decision and Market Authorization

Apple provided considerable evidence to support the regulatory decision, including detailed software documentation, algorithm verification and validation, preclinical testing, clinical performance data, risk management methods and cybersecurity considerations. Taken together, our findings showed that the Sleep Apnea Notification Feature worked as anticipated and did not create new safety and efficacy issues as compared with the predicate device. The FDA therefore determined that the device was sufficiently equivalent to a predicate device to be lawfully marketed for use in assessing the risk of sleep apnea in the intended adult population.

The approval of Apple's Sleep Apnea Notification Feature exemplifies the FDA's risk-based regulatory approach to SaMD, in which the FDA's regulatory decisions are based on objective scientific facts, not just technological innovation. The story also points to the necessity of integrating software quality, clinical validation, risk management and cybersecurity into the product development lifecycle to ensure patient safety and regulatory compliance.

Table II: Pre-market Notification

Device Classification Name:	**Over the counter Device to Assess Risk of Sleep Apnea**
Device Name	Sleep Apnea Notification Feature (SANF)
Classification Product Code	QZW
Date Received	04/04/2024
Decision Date	09/13/2024
Decision	Substantially Equivalent (SESE)
Regulation Medical Specialty	Anesthesiology
Review Panel	Anesthesiology
Premarket Review	Office of Ophthalmic, Anesthesia, Respiratory, ENT and Dental Devices (OHT1) Division of Anesthesia, Respiratory, and Sleep Devices (DHT1C)
Technical Method	The principle of operation is based on analyzing physiological signals to assess Sleep Apnea.
Target Area	Human body, Contactless or externally contacting device, Non-invasive, Non-implantable
Submission Type	510(k)
510k Number	K240929
Regulation Number	868.2378
Device Class	2
Combination Product	No
Implanted Device?	No
Life-Sustain/Support Device?	No

4. Software as a Medical Device: Regulatory Perspectives and Future Directions

Apple's successful FDA clearance of its Sleep Apnea Notification Feature provides valuable regulatory insights into the evolving approval landscape for SaMD. This case describes a technological innovation but also stresses the significance of including regulatory strategy, scientific data creation, software quality control, and patient safety considerations in the product development life cycle. The FDA's study shows that regulatory clearance of AI-enabled medical software requires a comprehensive evaluation of performance characteristics, including analytical validity, clinical performance, software reliability, risk management and cybersecurity, not just algorithmic performance. This case study explores regulatory considerations that may guide future SaMD developers seeking market authorization.

4.1 Early regulatory planning is important

Regulatory planning should be part of the earliest stages of software development, not merely at the time of regulatory submission. Early identification of the desired application, target patient population and the device classification and regulatory pathway to be followed can facilitate systematic evidence generation and minimization of regulatory review delays. A defined regulatory structure provides producers with a guide to designing appropriate validation studies, establishing software development processes and generating documentation that meets FDA standards. The successful regulatory path for Apple is an example that proactive regulatory planning is of great value for efficient product development and effective market authorization.

4.2 Developing Robust Scientific and Clinical Evidence

SaMD regulatory decisions are based on scientific facts. Manufacturers should demonstrate that the software results are analytically valid, therapeutically useful and reproducible under the intended conditions of use. The guarantee of software performance comes from comprehensive evidence generated from program production, software verification and validation, preclinical testing and clinical evaluation. Apple is emphasizing the necessity of creating high quality data that demonstrates both analytical and clinical validity and eliminates uncertainty in the regulatory review process by using clinical reference standards that are already established, by validating against independent data sets and by studying diverse populations.

4.3 Risk management within the software life cycle

Risk management remains a key regulatory expectation for Software as a Medical Device and should be applied throughout the software life cycle on a continuous basis. The potential risks of software failure, incorrect clinical outputs, cyber vulnerabilities and user related errors must be carefully recognized, assessed, managed and continually monitored. International standards such as ISO 14971 provide a standardized framework for risk management of medical devices and assist in regulatory compliance. The Apple case illustrates that proper risk management involves not only technical performance but also patient safety, benefit-risk evaluation and long-term software maintenance.

4.4 Software Quality, Security and Regulatory Compliance

As medical devices are becoming more integrated within digital healthcare ecosystems, software quality and cybersecurity have become increasingly significant components of regulatory scrutiny. Manufacturers should have full quality management systems in place including controls for software design, verification and validation, configuration management, change control, cybersecurity risk management, and post-market software maintenance. Protection of patient health information by secure software architecture, encryption, authentication procedures, and timely software upgrades further enhances regulatory confidence in software reliability. Apple's regulatory strategy shows that maintaining software quality and cybersecurity across the device life cycle is critical for regulatory compliance and continuing patient safety.

4.5 The Future of AI-Enabled Software as Medical Device

Artificial intelligence, machine learning and wearable digital health technologies are rapidly advancing and changing the future of Software as a Medical Device. Regulatory bodies worldwide are progressively embracing life cycle-based regulatory approaches focusing on continuous software monitoring, real-world performance evaluation, cybersecurity management and periodic software updates. Future regulations will likely allow more room for adaptive algorithms, while still retaining strong criteria for clinical validation and patient safety. Apple's Sleep Apnea Notification Feature receiving FDA clearance is a significant milestone in demonstrating how innovative digital health technologies can successfully achieve regulatory

authorization through comprehensive scientific evidence, robust quality management and adherence to established regulatory principles.

5. Implications for Global and Indian Regulatory Practice

The FDA's successful authorization of Apple's Sleep Apnea Notification Feature marks a significant step forward in the regulatory review of SaMD. This case illustrates regulatory approval of AI-enabled wearable medical solutions involving a holistic evidence-based approach to software quality, analytical and clinical validation, risk management, cybersecurity, and ongoing regulatory compliance. Apple's approach to regulation is applicable not just to a particular device, but also provides useful lessons for manufacturers, regulators and healthcare systems seeking to enable the safe integration of digital health technologies into clinical practice. "As the global growth in software driven healthcare solutions continues, the importance of harmonized regulatory approaches will grow to support innovation and at the same time ensure high standards of patient safety and product quality.

5.1 Impacts of Global Regulation

The regulatory landscape for SaMD has undergone a dramatic transformation with rapid breakthroughs in AI, wearable technology and digital health apps. The FDA and other regulatory agencies across the world are increasingly adopting a risk-based and life cycle-based approach to regulation, with a focus on continuous software quality assurance, clinical validation, cybersecurity and post-market performance monitoring. FDA's rigorous examination of software safety, effectiveness and clinical performance has made the agency's regulatory framework for SaMD an international benchmark.

The Apple case study illustrates the growing need for creating high quality scientific evidence throughout the software development life cycle. Software-enabled solutions are frequently updated, the algorithms refined and the cybersecurity strengthened after-market authorization, unlike conventional medical equipment. In this way, the regulatory oversight is shifting from a one-off premarket evaluation to ongoing lifecycle management including post-market surveillance, software maintenance, and real-world performance monitoring. This evolution of regulation stimulates innovation and assures the consistency of software performance across the product life cycle.

International organizations, including the IMDRFs, have played a significant role in harmonizing the regulatory principles for SaMD through the development of globally accepted frameworks for risk categorization, clinical evaluation, quality management, and lifecycle monitoring. Increased international harmonization can help to avoid duplication of regulation, improve access to global markets, and allow timely availability of novel digital health solutions – without sacrificing patient safety. The successful FDA clearance of Apple's device illustrates how adhering to internationally accepted regulatory norms can build regulatory confidence and speed up the adoption of wearable medical technologies in healthcare systems.

5.2 Implications for the Indian Regulatory Framework

The last decade has seen a boom in digital health technology in India, with wearable medical gadgets, telemedicine and AI-enabled healthcare apps mushrooming across the country. Initiatives like the Ayushman Bharat Digital Mission (ABDM) along with increasing spends towards digital healthcare infrastructure have spurred software driven healthcare solutions. The advent of these technologies in clinical practice has boosted the demand for a strong regulatory oversight of SaMD.

The Medical Device Rules, 2017 (the Rules) regulated as medical device by the CDSCO on the basis of the intended use and clinical risk of the software intended for medical purposes. But the fast-evolving AI-enabled software is raising rising regulatory issues including algorithm openness, adaptive learning systems, software modifications, cybersecurity, clinical validation, interoperability and post-market surveillance. Addressing these concerns would need the continued evolution of India's regulatory regime so that new digital health devices are covered by appropriate standards of safety, efficacy and quality during the life cycle.

The FDA's regulatory approach to Apple's Sleep Apnea Notification Feature offers key lessons for the future regulation of SaMD in India. Enhanced emphasis on structured software verification and validation, comprehensive clinical assessment, harmonized strategies for risk management, cybersecurity risk assessment, and lifecycle-based regulatory surveillance could boost regulatory decision making for software-enabled medical devices. Ongoing harmonization with internationally acknowledged standards like IEC 62304, ISO 14971 and the IMDRF SaMD guideline materials will perhaps foster global regulatory convergence and promote innovation within India's fast growing digital health ecosystem.

As India continues to strengthen its medical device regulatory ecosystem, collaborative engagement between regulatory authorities, healthcare professionals, software developers, academic institutions and industry stakeholders will be crucial in the development of evidence-based regulatory policies that foster innovation without compromising patient safety. Regulatory expertise from internationally cleared SaMD products such as Apple's Sleep Apnea Notification Feature could be a beneficial reference for future regulatory decision making in AI-enabled medical software in India.

5.3 Limitations

This case study was prepared using publicly available regulatory documents, FDA guidelines, and manufacturer supplied information. Proprietary software architecture, thorough verification reports, and internal regulatory correspondence were not available for independent examination because these are proprietary elements of the 510(k) filing. The current analysis represents publicly available information supporting FDA market authorization and should not be considered a complete account of all regulatory paperwork reviewed during the evaluation process.

Conclusion

FDA clearance of Apple's Sleep Apnea Notification feature is a key milestone in the regulation of SaMD and demonstrates how innovative digital health solutions may successfully navigate complicated regulatory requirements through the development of a strong body of scientific evidence. The case study demonstrates that regulatory approval is not only a matter of technological innovation, but requires a multidisciplinary strategy that includes software quality management, analytical and clinical validation, risk management, cyber security and regulatory compliance throughout the product lifetime.

Apple's successful usage of the Premarket Notification (510(k)) pathway is a good example of the importance of building software development with regulatory requirements in mind from the beginning of product creation. The manufacturer was able to show substantial equivalence with reasonable assurance of the safety, effectiveness, and reliability of the device by systematically generating objective evidence through the development of algorithms, verification and validation of software, pre-clinical testing, and clinical evaluation. The concepts of regulation are still vital to the successful development and commercialization of future Software as a Medical Device.

The role of artificial intelligence, smart technology and digital health solutions in revolutionizing the healthcare services across the globe will keep evolving. That will mean that regulators will have to continuously evolving their frameworks to keep up with the new challenges of adaptive algorithms, cybersecurity, real-world performance monitoring and continuous software updates. A combination of global regulatory standards and lifecycle-based regulation will be more important to promote ingenuity and ensure patient safety.

To summarize, the regulatory pathway chosen for Apple's SANF is a good example of evidence-based regulatory decision-making for SaMD. The results of this case study can contribute to the development of scientifically sound and globally harmonized approaches by manufacturers, researchers and regulatory authorities for the assessment of future AI-enabled medical software supporting the safe integration of digital health technologies into modern health care systems.

Acknowledgements

The author acknowledges the publicly available FDA guidance documents, market authorization records, and scientific information that served as a valuable reference resource and contributed to the preparation of this regulatory case study.

Funding

The author received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors for the preparation of this manuscript.

Conflict of Interest

The authors declares that there are no conflicts of interest regarding the publication of this manuscript.

Data Availability

No new datasets were generated or analyzed during the preparation of this review. All information presented in this manuscript was obtained from publicly available regulatory documents, guidance publications, scientific literature, and official sources cited in the reference list.

Reference:

1. International Medical Device Regulators Forum. Software as a Medical Device (SaMD): Key Definitions. Available from: https://www.imdrf.org
2. International Medical Device Regulators Forum. Software as a Medical Device (SaMD): Possible Framework for Risk Categorization and Corresponding Considerations. Available from: https://www.imdrf.org
3. International Medical Device Regulators Forum. Software as a Medical Device (SaMD): Clinical Evaluation. Available from: https://www.imdrf.org
4. U.S. Food and Drug Administration. Content of Premarket Submissions for Device Software Functions: Guidance for Industry and Food and Drug Administration Staff. Available from: https://www.fda.gov/medical-devices/device-software-functions
5. U.S. Food and Drug Administration. Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions. Available from: https://www.fda.gov
6. U.S. Food and Drug Administration. Medical Device Reporting (MDR). Available from: https://www.fda.gov
7. U.S. Food and Drug Administration. Premarket Notification (510(k)) Database. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm
8. U.S. Food and Drug Administration. 510(k) Summary K240929: Apple Sleep Apnea Notification Feature. Available from: https://www.accessdata.fda.gov
9. Apple Inc. Sleep Apnea Notifications on Apple Watch. Available from: https://www.apple.com/healthcare
10. Apple Inc. Breathing Disturbances and Sleep Apnea Notifications Validation Study. Available from: https://www.apple.com/healthcare
11. Muehlematter UJ, Daniore P, Vokinger KN. Approval of artificial intelligence and machine learning-based medical devices in the USA and Europe. Nat Mach Intell. 2021;3(9):738-739.
12. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44-56.
13. Kelly CJ, Karthikesalingam A, Suleyman M, Corrado G, King D. Key challenges for delivering clinical impact with artificial intelligence. BMC Med. 2019;17(1):195.
14. Rajpurkar P, Chen E, Banerjee O, Topol EJ. AI in health and medicine. Nat Med. 2022;28(1):31-38.
15. International Electrotechnical Commission. IEC 62304: Medical Device Software—Software Life Cycle Processes. Geneva: International Electrotechnical Commission.
16. International Organization for Standardization. ISO 14971: Medical Devices—Application of Risk Management to Medical Devices. Geneva: International Organization for Standardization.
17. World Health Organization. Global Strategy on Digital Health 2020-2025. Available from: https://www.who.int
18. World Health Organization. Global Observatory for eHealth. Available from: https://www.who.int
19. Benjafield AV, Ayas NT, Eastwood PR, Heinzer R, Ip MSM, Morrell MJ, et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. Lancet Respir Med. 2019;7(8):687-698.
20. Kapur VK, Auckley DH, Chowdhuri S, Kuhlmann DC, Mehra R, Ramar K, Harrod CG. Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea. J Clin Sleep Med. 2017;13(3):479-504.
21. U.S. Department of Health and Human Services. Digital Health Innovation Action Plan. Available from: https://www.hhs.gov

22. U.S. Food and Drug Administration. Artificial Intelligence and Machine Learning (AI/ML)-Enabled Medical Devices. Available from: https://www.fda.gov